Orthofix Medical, Inc. OFIX

Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...

Orthofix Medical Inc (OFIX) delivers 5% pro forma growth, raises EBITDA guidance, and navigates a complex landscape of European MDR opportunities and U.S. distributor headwinds.

Moby summary of Orthofix Medical Inc.'s Q2 2026 earnings call

Orthofix (OFIX) delivered earnings and revenue surprises of +333.33% and +0.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

LEWISVILLE, Texas, August 05, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines.

Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. A copy of the letter can be downloaded here. Rewey Asset Management, an investment management firm, released its “RAM Smid Composite” investor letter for the second quarter of 2026. RAM Smid Composite gained 20.06% in the […]

eXeX, the global Surgery Intelligence company, today announced the appointment of Max Reinhardt as President, Healthcare. Reinhardt, who has held senior leadership roles in MedTech and pharmaceuticals, will drive the company's commercial execution, bringing Surgery Intelligence into hospital systems across the United States, the United Kingdom, and beyond.

LEWISVILLE, Texas, July 20, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences:

LEWISVILLE, Texas, July 15, 2026--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

Orthofix Medical Inc. (NASDAQ:OFIX) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has declined roughly 22% since its fiscal Q1 2026 earnings. Despite the softness, the Street remains bullish, with analysts’ 12-month price target suggesting more than 54% upside from the current level. ​Orthofix Medical Inc. (NASDAQ:OFIX) released earnings […]

The latest analyst update on Orthofix Medical keeps the model fair value steady at US$15.0 per share, signaling no reset to the core price target despite refreshed assumptions. This stable fair value sits against a backdrop of mixed analyst commentary, with some focusing on the reset in reimbursement expectations for non invasive bone growth stimulators and others stressing the earnings headwind from the new CMS framework. As you read on, you will see how these shifting views shape the...

Orthofix Medical is back in focus after a recent reset of its fair value estimate, with the price target moving from US$17.25 to US$15.00, a cut of about 13%. That change lines up with a Street narrative that mixes caution and optimism as analysts weigh the impact of CMS reimbursement updates and the company’s revised long term outlook. Read on to see how different analysts are framing this reset and how you can follow the story as it continues to evolve. Wall Street's queuing for one rocket...